Here are the 2 big things we're watching in the stock market in the week ahead

Next week’s focus is July CPI and PPI, with economists targeting 3.4% headline CPI and 2.5% core CPI YoY, plus PPI gains of +0.1% (headline) and +0.3% (core) MoM; Fed officials warn inflation risks now outweigh employment risks given AI data-center capex and energy/inputs pressure. The Fed backdrop is also mixed after July nonfarm payrolls fell 23,000 vs +83,000 expected and wage inflation softened, even as unemployment edged down to 4.1%. On the company front, Cardinal Health (CAH) reports fiscal 2026 Q4 with LSEG consensus at $65.03B revenue and $2.42 EPS, as investors look for clean beats and commentary on higher-margin specialty/nuclear medicine amid GLP-1 and Alzheimer’s-drug related diagnostic momentum.

Analysis

The market is treating inflation as a single-input story, but the bigger mechanism is sticky price pressure from both energy and AI-related capex. That matters because it keeps the Fed boxed in even if headline data cools, which is a bad mix for long-duration equities and any business model dependent on falling financing costs. In that setup, the winners are less the obvious energy names and more cash-generative, short-duration balance-sheet stories; the losers are housing, rate-sensitive consumer names, and high-multiple software/equipment where valuation is doing too much work.

The non-obvious second-order effect is that AI infrastructure can be inflationary before it becomes productivity-enhancing: power, copper, specialty equipment, and labor all get bid first, while the margin benefit is deferred. That argues for caution on duration-heavy AI proxies even if end-demand is intact; a hotter PPI/CPI print would compress multiples faster than it boosts near-term bookings. If retail sales soften at the same time, the market can pivot from soft-landing to stagflation-lite, which is typically the worst regime for cyclicals and home-related exposure.

On the single-name side, the healthcare distributor setup is more about mix than headline beats. The stock can hold near highs only if specialty, nuclear medicine, and the newer home-health assets prove they are widening gross margin, not just adding revenue. The peer bar is already high, so any guidance conservatism or evidence that the profitable growth engines are still too small will likely trigger a de-rating rather than a dramatic absolute selloff.

Contrarian view: consensus is still too anchored to the idea that softer payrolls automatically buy the Fed room to ease. If inflation remains firm in services and AI-linked inputs, the central bank may stay on hold longer than the market wants, and the real trade is not "hot data bad" but "hot data + weak labor = higher real-rate pressure."

Key Decisions for Investors

• Initiate a tactical short in TLT or IEF into Wednesday/Thursday CPI-PPI, sized as a 1-2 week rates hedge. Falsify if core CPI prints <=0.2% m/m and PPI is flat-to-negative, which would likely force a relief rally in duration.
• Buy a small CAH call spread or keep a starter long only into the print; upside depends on FY27 guidance and specialty/nuclear margin mix, not just EPS. Take profits on any post-earnings gap if guidance is merely in-line; thesis breaks on revenue miss or flat specialty commentary.
• Pair long GEHC vs. short COR/MCK on the view that radiopharma and diagnostic imaging have the cleaner incremental growth from Alzheimer's/PET adoption than generic distribution. Use a 1-3 month horizon; exit if GEHC commentary shows no Vizamyl acceleration.
• Use HD as a retail/housing hedge against a hot inflation print: short on a CPI/PPI upside surprise or weak retail sales signal. Cover if retail sales beat and real yields fall, because the market would shift back toward a softer landing narrative.